Proteomics Collaborations: A Comprehensive Review (2010-2023) with Access to Headline, Upfront, Milestone & Royalty Data
2023-06-30
DUBLIN, June 30, 2023 /PRNewswire/ -- The "Global Proteomics Partnering Terms and Agreements 2010 to 2023" report has been added to
ResearchAndMarkets.com's offering.
The Global Proteomics Partnering Terms and Agreements 2010 to 2023 report provides an understanding and access to the proteomics partnering deals and agreements entered into by the world's leading healthcare companies.
Trends in proteomics dealmaking in the biopharma industry since 2010
Access to headline, upfront, milestone and royalty data
Access to over 600 proteomics deal records and contract documents where available
The leading proteomics deals by value since 2010
Most active proteomics dealmakers since 2010
The leading proteomics partnering resources
The Global Proteomics Partnering Terms and Agreements report provides an understanding and access to the proteomics partnering deals and agreements entered into by the world's leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of proteomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in proteomics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading proteomics deals since 2010. Deals are listed by headline value, signed by big pharma, most active proteomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in proteomics dealmaking with a brief summary followed by a comprehensive listing of proteomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of proteomics partnering deals signed and announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of proteomics partnering deals signed and announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Proteomics partnering company A-Z, deal type definitions and proteomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in proteomics partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of proteomics technologies and products.
Key Topics Covered
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in proteomics dealmaking
2.1. Introduction
2.2. Proteomics partnering over the years
2.3. Most active proteomics dealmakers
2.4. Proteomics partnering by deal type
2.5. Proteomics partnering by therapy area
2.6. Deal terms for proteomics partnering
2.6.1 Proteomics partnering headline values
2.6.2 Proteomics deal upfront payments
2.6.3 Proteomics deal milestone payments
2.6.4 Proteomics royalty rates
Chapter 3 - Leading proteomics deals
3.1. Introduction
3.2. Top proteomics deals by value
Chapter 4 - Most active proteomics dealmakers
4.1. Introduction
4.2. Most active proteomics dealmakers
4.3. Most active proteomics partnering company profiles
Chapter 5 - Proteomics contracts dealmaking directory
5.1. Introduction
5.2. Proteomics contracts dealmaking directory
Chapter 6 - Proteomics dealmaking by technology type
Appendices
Appendix 1 - Proteomics deals by company A-Z
Appendix 2 - Proteomics deals by stage of development
Appendix 3 - Proteomics deals by deal type
Appendix 4 - Proteomics deals by therapy area
Deal type definitions
Companies Mentioned
20/20 BioResponse
21st Century Biochemicals
A*STAR Bioinformatics Institute
A*STAR Genome Institute of Singapore
A*STAR Institute of Microelectronics (IME)
Abnova
Academy for Medical Development & Collaboration
ACGT
Activiomics
Advaita
Advanced Biological Laboratories
AEterna Zentaris
AGTC
Aileron TherapeuticsAileron Therapeutics
Allergan
Almac GroupAlmac Group
Almirall
Alzheimers Research UK
AmorChem
Amplimmune
Antigen Discovery
Antitope
Applied Proteomics
Ariadne Genomics
Aspera
Asuragen
Autism Speaks
Autogenesis
Avera Heart Hospital of South Dakota
Axil Scientific
Bayer
Berg
Bill and Melinda Gates Foundation
Biocrates
Bioeasy Diagnostica
BioFocus
Biomodels
Bio Sidus Argentina
BioSystem Development
Biotage
Biotechnology and Biological Sciences Research Council (BBSRC)
Biotechnology Value Fund
bioVidria
Bioyong
BluePen Biomarkers
Bruker
Bucher Biotec
Bulldog Bio
c-LEcta
Calixar
Camino Partnership
Cancer Research Technology
Cancer Research UK
For more information about this report visit https://www.researchandmarkets.com/r/kupayf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。